, Annexe 3 : Isolement de mitochondries, MACS mitochondria isolation kit, human

, Reprendre les culots cellulaires obtenus à partir des différentes conditions traitées à raison de 10 7 cellules dans 10 mL de PBS

, Centrifuger pendant 10 minutes à 300 g, 4 °C, puis éliminer le surnageant

, Reprendre chaque culot cellulaire dans 200 µL de Lysis Buffer froid

, Centrifuger pendant 2 minutes à 13.000 g, 4 °C, puis éliminer le surnageant

, Dans l'attente d'un dosage de protéines par la méthode BCA et d'un dosage du platine par ICP-MS sur les échantillons ainsi obtenus de mitochondries isolées

S. S. Agarwala and J. M. Kirkwood, Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma, The Oncologist, vol.5, issue.2, pp.144-51, 2000.

W. Akerley, A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone, Cancer, vol.94, issue.6, pp.1654-60, 2002.

A. M. Al-abd, Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies -A review, Journal of Advanced Research, vol.8, issue.6, pp.591-605, 2017.

I. Alagkiozidis, Metronomic cyclophosphamide with bevacizumab provides disease stabilization in patients with advanced uterine cancer, Gynecologic Oncology Reports, vol.12, pp.23-29, 2015.

S. N. Alconcel, A. S. Baas, and H. D. Maynard, FDA-approved poly(ethylene glycol)-protein conjugate drugs, Polymer Chemistry, vol.2, issue.7, p.1442, 2011.

L. Amable, Cisplatin resistance and opportunities for precision medicine, Pharmacological Research, vol.106, pp.27-36, 2016.

M. M. Amiji, Intratumoral administration of paclitaxel in an in situ gelling poloxamer 407 formulation, Pharmaceutical Development and Technology, vol.7, issue.2, pp.195-202, 2002.

C. P. Anderson, Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma, Pediatric Blood & Cancer, vol.62, issue.10, pp.1739-1785, 2015.

P. Anderson, Outpatient chemotherapy plus radiotherapy in sarcomas: Improving cancer control with radiosensitizing agents, Cancer Control, vol.15, issue.1, pp.38-46, 2008.

A. Arshad, Convection-enhanced delivery of carboplatin PLGA nanoparticles for the treatment of glioblastoma, PLoS ONE, vol.10, issue.7, p.132266, 2015.

D. Artemov, Molecular magnetic resonance imaging with targeted contrast agents, Journal of Cellular Biochemistry, vol.90, issue.3, pp.518-542, 2003.

P. Baas, Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.26, pp.31-39, 2015.

M. Baba, Micellization of cisplatin (NC-6004) reduces its ototoxicity in guinea pigs, Journal of Controlled Release, vol.157, issue.1, pp.112-119, 2012.

N. J. Babu, Temozolomide hydrochloride dihydrate, CrystEngComm, vol.15, issue.4, pp.666-71, 2013.

I. Baldi, Épidémiologie des glioblastomes, Neurochirurgie, vol.56, issue.6, pp.433-473, 2010.

R. M. Baldwin, Protection of glioblastoma cells from cisplatin cytotoxicity via protein kinase C?-mediated attenuation of p38 MAP kinase signaling, Oncogene, vol.25, issue.20, pp.2909-2928, 2006.

S. S. Banerjee, Poly(ethylene glycol)-prodrug conjugates: Concept, design, and applications, Journal of Drug Delivery, pp.1-17, 2012.

R. F. Barth, Comparison of intracerebral delivery of carboplatin and photon irradiation with an optimized regimen for boron neutron capture therapy of the F98 rat glioma, Applied Radiation and Isotopes, vol.69, issue.12, pp.1813-1819, 2011.

N. U. Barua, Convection-enhanced delivery of MANF -Volume of distribution analysis in porcine putamen and substantia nigra, Journal of the Neurological Sciences, vol.357, issue.1-2, pp.264-273, 2015.

R. Baskar, Cancer and radiation therapy: Current advances and future directions, International Journal of Medical Sciences, vol.9, issue.3, pp.193-202, 2012.

P. Bateson, The nest's tale. A reply to Richard Dawkins, Biology and Philosophy, vol.21, issue.4, pp.553-561, 2006.

E. V. Batrakova, S. Li, and W. F. Elmquist, Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: Selective energy depletion, British Journal of Cancer, vol.85, issue.12, pp.1987-97, 2001.

E. V. Batrakova, S. Li, and S. V. Vinogradov, Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: Contributions of energy depletion and membrane fluidization, The Journal of Pharmacology and Experimental Therapeutics, vol.299, issue.2, pp.483-93, 2001.

D. N. Bell, Specific determination of intact cisplatin and monohydrated cisplatin in human plasma and culture medium ultrafiltrates using HPLC on-line with inductively coupled plasma mass spectrometry, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol.837, issue.1-2, pp.29-34, 2006.

J. Bellmunt, Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.25, pp.40-48, 2014.

A. Bencsik and P. Lestaevel, Concerns regarding nanosized titanium dioxide nasal exposure and neurotoxicity study by Ze et al, Journal of Biomedical Materials Research Part A, vol.103, issue.6, pp.2198-200, 2015.

A. Bencsik, Le cerveau est-il à l'abri d'un impact d'une exposition à des nanomatériaux ?, Biologie Aujourd'hui, vol.208, issue.2, pp.159-65, 2014.

M. Benedetti, Experimental evidence that a DNA polymerase can incorporate N7-platinated guanines to give platinated DNA, Angewandte Chemie International Edition, vol.47, issue.3, pp.507-517, 2008.

M. Benedetti, Possible incorporation of free N7-platinated guanines in DNA by DNA polymerases, relevance for the cisplatin mechanism of action. In Platinum and Other Heavy Metal Compounds in Cancer, pp.125-157, 2009.

S. Benzina, Cell death induced in a human glioblastoma cell line by p(65)+Be neutrons combined with cisplatin, Life Sciences, vol.79, issue.6, pp.513-521, 2006.

M. Biston, Cure of Fisher rats bearing radioresistant F98 glioma treated with cis-platinum and irradiated with monochromatic synchrotron X-rays, Cancer Research, vol.64, issue.7, pp.2317-2340, 2004.
URL : https://hal.archives-ouvertes.fr/inserm-00388956

K. B. Bjugstad, Biocompatibility of poly(ethylene glycol)-based hydrogels in the brain: An analysis of the glial response across space and time, Journal of Biomedical Materials Research. Part A, vol.95, issue.1, pp.79-91, 2010.

R. H. Bobo, Convection-enhanced delivery of macromolecules in the brain, Proceedings of the National Academy of Sciences, vol.91, issue.6, pp.2076-80, 1994.

L. Bobyk, Intracerebral delivery of carboplatin in combination with either 6 MV photons or monoenergetic synchrotron X-rays are equally efficacious for treatment of the F98 rat glioma, Journal of Experimental & Clinical Cancer Research, vol.31, p.78, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00759750

T. Boulikas, Clinical overview on Lipoplatin ? : A successful liposomal formulation of cisplatin, Expert Opinion on Investigational Drugs, vol.18, issue.8, pp.1197-218, 2009.

K. Bourzac, Nanotechnology: Carrying drugs, Nature, issue.7425, pp.58-60, 2012.

R. D. Boyd, S. K. Pichaimuthu, and A. Cuenat, New approach to inter-technique comparisons for nanoparticle size measurements; using atomic force microscopy, nanoparticle tracking analysis and dynamic light scattering, Colloids and Surfaces A: Physicochemical and Engineering Aspects, vol.387, issue.1-3, pp.35-42, 2011.

S. Bracard, Imagerie cérébrale des gliomes : Diagnostic et suivi conventionnels, C2), vol.87, pp.779-91, 2006.

L. Bregoli, Nanomedicine applied to translational oncology: A future perspective on cancer treatment, Nanomedicine: Nanotechnology, Biology, and Medicine, vol.12, issue.1, pp.81-103, 2016.

A. Bregy, The role of Gliadel wafers in the treatment of high-grade gliomas, Expert Review of Anticancer Therapy, vol.13, issue.12, pp.1453-61, 2013.

P. Brookes and P. D. Lawley, Alkylating agents, British Medical Bulletin, vol.20, issue.2, pp.91-96, 1964.

G. J. Bubley, Effect of DNA conformation on cisplatin adduct formation, Biochemical Pharmacology, vol.51, issue.5, pp.717-738, 1996.

A. Burgess, Focused ultrasound-mediated drug delivery through the blood-brain barrier, Expert Review of Neurotherapeutics, vol.15, issue.5, pp.477-91, 2015.

C. Burtea, Contrast agents: Magnetic resonance, Handbook of Experimental, pp.135-65, 2008.

H. Cabral and K. Kataoka, Progress of drug-loaded polymeric micelles into clinical studies, Journal of Controlled Release, vol.190, pp.465-76, 2014.

H. Cabral, Preparation and biological properties of dichloro(1,2-diaminocyclohexane) platinum(II) (DACHPt)-loaded polymeric micelles, Journal of Controlled Release, vol.101, pp.223-255, 2005.

Y. Cai, Supramolecular "Trojan Horse" for nuclear delivery of dual anticancer drugs, Journal of the American Chemical Society, vol.139, issue.8, pp.2876-2885, 2017.

S. Cajot, Design of reversibly core cross-linked micelles sensitive to reductive environment, Journal of Controlled Release, vol.152, issue.1, pp.30-36, 2011.

S. Cajot, Smart nanocarriers for pH-triggered targeting and release of hydrophobic drugs, Acta Biomaterialia, vol.8, issue.12, pp.4215-4238, 2012.

S. Cajot, Novel functional degradable block copolymers for the building of reactive micelles, Polym. Chem, vol.4, issue.4, pp.1025-1062, 2013.

S. Cajot and N. Lautram, Design of reversibly core cross-linked micelles sensitive to reductive environment, Journal of Controlled Release, vol.152, issue.1, pp.30-36, 2011.

S. Cajot and R. Riva, Novel amphiphilic mikto-arm star-shaped copolymers for the preparation of PLA-based nanocarriers, Macromolecular Symposia, pp.111-133, 2011.

Y. Cao, Photo-triggered fluorescent theranostic prodrugs as DNA alkylating agents for mechlorethamine release and spatiotemporal monitoring, Organic & Biomolecular Chemistry, vol.13, issue.24, pp.6742-6750, 2015.

P. Caravan, Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium-and manganese-based T1 contrast agents, Contrast Media & Molecular Imaging, vol.4, issue.2, pp.89-100, 2009.

S. Carlotti and F. Peruch, Cyclic monomers: Epoxides, lactide, lactones, lactams, cyclic silicon-containing monomers, cyclic carbonates, and others, pp.191-305, 2015.

B. L. Carlson, Radiosensitizing effects of TMZ observed in vivo only in a subset of MGMT methylated GBM xenografts, International Journal of Radiation Oncology, vol.75, issue.1, pp.212-221, 2009.

S. K. Carlsson, S. P. Brothers, and C. Wahlestedt, Emerging treatment strategies for glioblastoma multiforme, EMBO Molecular Medicine, vol.6, issue.11, pp.1359-70, 2014.

P. Cassier, New developments in treatment of ovarian carcinoma: Focus on trabectedin, Cancer Management and Research, vol.2, pp.233-275, 2010.

A. J. Chalmers, Cytotoxic effects of temozolomide and radiation are additive-and schedule-dependent, International Journal of Radiation Oncology Biology Physics, vol.75, issue.5, pp.1511-1520, 2009.

A. T. Chan, Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.23, issue.7, pp.83-85, 2012.

R. Chapanian, The role of oxidation and enzymatic hydrolysis on the in vivo degradation of trimethylene carbonate based photocrosslinkable elastomers, Biomaterials, vol.30, issue.3, pp.295-306, 2009.

G. Charest, Concomitant treatment of F98 glioma cells with new liposomal platinum compounds and ionizing radiation, Journal of Neuro-Oncology, vol.97, issue.2, pp.187-93, 2010.

C. Chargari, Cancer stem cells, cornerstone of radioresistance and perspectives for radiosensitization: Glioblastoma as an example, Bulletin du Cancer, vol.99, issue.12, pp.1153-60, 2012.

H. H. Chen and M. T. Kuo, Role of glutathione in the regulation of cisplatin resistance in cancer chemotherapy, Metal-Based Drugs, pp.1-7, 2010.

H. Chen, Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas, International Journal of Cancer, vol.126, issue.8, pp.1944-54, 2010.

W. Chen, MiR-136 targets E2F1 to reverse cisplatin chemosensitivity in glioma cells, Journal of Neuro-Oncology, vol.120, issue.1, pp.43-53, 2014.

X. Chen, MiR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2, International Journal of Oncology, vol.47, issue.4, pp.1603-1614, 2015.

Y. Cheng, Multifunctional nanoparticles for brain tumor imaging and therapy, Advanced Drug Delivery Reviews, vol.66, pp.42-57, 2014.

K. Cheung-ong, G. Giaever, and C. Nislow, DNA-damaging agents in cancer chemotherapy: Serendipity and chemical biology, Chemistry and Biology, vol.20, issue.5, pp.648-59, 2013.

C. Salome, A. Onunkwo-godswill, C. Onyishi-ikechukwu, and I. , Kinetics and mechanisms of drug release from swellable and non swellable matrices: A review, Research Journal of Pharmaceutical, Biological and Chemical Sciences, vol.4, issue.2, pp.97-103, 2013.

Y. M. Choi, Mechanism of cisplatin-induced cytotoxicity is correlated to impaired metabolism due to mitochondrial ROS generation, PLoS ONE, vol.10, issue.8, p.135083, 2015.

N. Colombo, Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.23, pp.20-26, 2012.

T. A. Connors, Alkylating agents, Topics in Current Chemistry, vol.52, pp.141-71, 1974.

P. Correale, Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients, Cancer Biology and Therapy, vol.9, issue.9, pp.685-93, 2010.

P. Correale, Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients, Cancer Biology and Therapy, vol.12, issue.2, pp.112-120, 2011.

M. Corte-rodríguez, Quantitative evaluation of cellular uptake, DNA incorporation and adduct formation in cisplatin sensitive and resistant cell lines: Comparison of different Pt-containing drugs, Biochemical Pharmacology, vol.98, issue.1, pp.69-77, 2015.

C. M. Croce, Causes and consequences of microRNA dysregulation in cancer, Nature Reviews Genetics, vol.10, issue.10, pp.704-718, 2009.

K. J. Cullen, Mitochondria as a critical target of the chemotherapeutic agent cisplatin in head and neck cancer, Journal of Bioenergetics and Biomembranes, vol.39, issue.1, pp.43-50, 2007.

G. Damia and M. D'incalci, Mechanisms of resistance to alkylating agents, Cytotechnology, vol.27, issue.1-3, pp.165-73, 1998.

A. S. Darefsky, J. T. King, and R. Dubrow, Adult glioblastoma multiforme survival in the temozolomide era: A population-based analysis of Surveillance, Epidemiology, and End Results registries, Cancer, vol.118, issue.8, pp.2163-72, 2012.

S. Dasari and P. B. Tchounwou, Cisplatin in cancer therapy: Molecular mechanisms of action, European Journal of Pharmacology, vol.740, pp.364-78, 2014.

T. K. Dash and V. B. Konkimalla, Poly-?-caprolactone based formulations for drug delivery and tissue engineering: A review, Journal of Controlled Release, vol.158, issue.1, pp.15-33, 2012.

M. Davis, Glioblastoma: Overview of disease and treatment, Clinical Journal of Oncology Nursing, vol.20, issue.5, pp.2-8, 2016.

F. De-felice, D. Musio, and V. Tombolini, Head and neck cancer: Metronomic chemotherapy, BMC Cancer, vol.15, p.677, 2015.

T. Defize, Multifunctional poly(?-caprolactone)-forming networks by diels-alder cycloaddition: Effect of the adduct on the shape-memory properties, Macromolecular Chemistry and Physics, vol.213, issue.2, pp.187-97, 2012.

J. W. Degen, Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats, Journal of Neurosurgery, vol.99, issue.5, pp.893-901, 2003.

G. Delaney, The role of radiotherapy in cancer treatment, Cancer, vol.104, issue.6, pp.1129-1166, 2005.

R. Delorme, Comparison of gadolinium nanoparticles and molecular contrast agents for radiation therapy-enhancement, Medical Physics, vol.44, issue.11, p.239, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01690606

V. T. Devita and E. Chu, A history of cancer chemotherapy, Cancer Research, vol.68, issue.21, pp.8643-53, 2008.

P. J. Dickinson, Canine spontaneous glioma: A translational model system for convection-enhanced delivery, Neuro-Oncology, vol.12, issue.9, pp.928-968, 2010.

D. Ding, Cisplatin-loaded gelatin-poly(acrylic acid) nanoparticles: Synthesis, antitumor efficiency in vivo and penetration in tumors, European Journal of Pharmaceutics and Biopharmaceutics, vol.79, issue.1, pp.142-151, 2011.

G. J. Doherty and H. T. Mcmahon, Mechanisms of endocytosis, Annual Review of Biochemistry, vol.78, issue.1, pp.857-902, 2009.

T. A. Dolecek, CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the united states in, Neuro-Oncology, vol.14, pp.1-49, 2005.

T. A. Dolecek, CBTRUS statistical report : Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010, Neuro-Oncology, vol.12, issue.1, pp.28-36, 2013.

R. F. Domingos, Characterizing manufactured nanoparticles in the environment: Multimethod determination of particle sizes, Environmental Science and Technology, vol.43, issue.19, pp.7277-84, 2009.

G. Dresemann, Temozolomide in malignant glioma, OncoTargets and Therapy, vol.3, pp.139-185, 2010.

B. J. Druker, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia, The New England Journal of Medicine, vol.355, issue.23, pp.2408-2425, 2006.

X. Duan, Polymeric micelle-mediated delivery of DNA-targeting organometallic complexes for resistant ovarian cancer treatment, Small, vol.11, issue.32, pp.3962-72, 2015.

F. Ducray and R. Guillevin, Caractéristiques radiologiques des glioblastomes, vol.11, pp.1-2, 2007.

A. Eastman, The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes, Pharmacology and Therapeutics, vol.34, issue.2, pp.155-66, 1987.

F. Eckert, Definitive radiotherapy and single-agent radiosensitizing ifosfamide in patients with localized, irresectable soft tissue sarcoma: A retrospective analysis, Radiation Oncology, vol.5, issue.1, p.55, 2010.

M. Edgren and B. Lennernäs, Estramustine a radio sensitising agent, Anticancer Research, vol.20, issue.4, pp.2677-80, 2000.

P. Ehrlich, Collected studies on immunity, 1906.

A. C. Engler, Accessing new materials through polymerization and modification of a polycarbonate with a pendant activated ester, Macromolecules, vol.46, issue.4, pp.1283-90, 2013.

A. C. Engler, Hydrophilic polycarbonates: Promising degradable alternatives to poly(ethylene glycol)-based stealth materials, Macromolecules, vol.48, issue.6, pp.1673-1681, 2015.

B. Erdlenbruch, Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients, European Journal of Clinical Pharmacology, vol.57, issue.5, pp.393-402, 2001.

E. Bosch and M. , Analytical methodologies for the determination of cisplatin, Journal of Pharmaceutical and Biomedical Analysis, vol.47, pp.451-460, 2008.

A. A. Exner, Enhancement of carboplatin toxicity by Pluronic block copolymers, Journal of Controlled Release, vol.106, issue.1-2, pp.188-97, 2005.

C. H. Fan and C. K. Yeh, Microbubble-enhanced focused ultrasound-induced blood-brain barrier opening for local and transient drug delivery in central nervous system disease, Journal of Medical Ultrasound, vol.22, issue.4, pp.183-93, 2014.

F. Fehlauer, Additive cytotoxic effect of cisplatin and X-irradiation on human glioma cell cultures derived from biopsy-tissue, Journal of Cancer Research and Clinical Oncology, vol.126, issue.12, pp.711-717, 2000.

F. Fehlauer, Effects of irradiation and cisplatin on human glioma spheroids: Inhibition of cell proliferation and cell migration, Journal of Cancer Research and Clinical Oncology, vol.131, issue.11, pp.723-755, 2005.

D. A. Fennell, Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer, Cancer Treatment Reviews, vol.44, pp.42-50, 2016.

C. Fernandes, Current standards of care in glioblastoma therapy, Glioblastoma. Codon Publications, pp.197-241, 2017.

G. Ferrandina, Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: A retrospective, multicenter study, Gynecologic Oncology, vol.130, issue.3, pp.505-515, 2013.

V. Filipe, A. Hawe, and W. Jiskoot, Critical evaluation of nanoparticle tracking analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates, Pharmaceutical Research, vol.27, issue.5, pp.796-810, 2010.

M. Filippousi, Biocompatible Zr-based nanoscale MOFs coated with modified poly(?-caprolactone) as anticancer drug carriers, International Journal of Pharmaceutics, vol.509, issue.1-2, pp.208-226, 2016.

K. Fizazi, Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.26, pp.64-68, 2015.

S. B. Fonseca, Rerouting chlorambucil to mitochondria combats drug deactivation and resistance in cancer cells, Chemistry & Biology, vol.18, issue.4, pp.445-53, 2011.

Y. A. Fouad and C. Aanei, Revisiting the hallmarks of cancer, American Journal of Cancer Research, vol.7, issue.5, pp.1016-1052, 2017.

H. Freichels and D. Alaimo, ?-Acetal, ?-alkyne poly(ethylene oxide) as a versatile building block for the synthesis of glycoconjugated graft-copolymers suited for targeted drug delivery, Bioconjugate Chemistry, vol.23, issue.9, pp.1740-52, 2012.

H. Freichels and F. Danhier, Fluorescent labeling of degradable poly(lactide-coglycolide) for cellular nanoparticles tracking in living cells, The International Journal of Artificial Organs, vol.34, issue.2, pp.152-60, 2011.

H. Freichels, R. Jérôme, and C. Jérôme, Sugar-labeled and PEGylated (bio)degradable polymers intended for targeted drug delivery systems, Carbohydrate Polymers, vol.86, issue.3, pp.1093-106, 2011.

H. Freichels and V. Pourcelle, Synthesis of poly(lactide-co-glycolide-co-?-caprolactone)-graft-mannosylated poly(ethylene oxide) copolymers by combination of "clip" and "click" chemistries, Biomacromolecules, vol.13, issue.3, pp.760-768, 2012.

M. Früh, Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.24, pp.99-105, 2013.

Y. Fu and W. J. Kao, Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems, Expert Opinion Drug Delivery, vol.7, issue.4, pp.429-473, 2010.

O. Gallego, Nonsurgical treatment of recurrent glioblastoma, Current Oncology, vol.22, issue.4, pp.273-81, 2015.

J. A. Gallego-urrea, J. Tuoriniemi, and M. Hassellöv, Applications of particle-tracking analysis to the determination of size distributions and concentrations of nanoparticles in environmental, biological and food samples, Trends in Analytical Chemistry, vol.30, issue.3, pp.473-83, 2011.

L. Galluzzi, Molecular mechanisms of cisplatin resistance, Oncogene, issue.15, pp.1869-83, 2012.

L. Galluzzi, Systems biology of cisplatin resistance: Past, present and future, Cell Death and Disease, vol.5, issue.5, pp.1257-1275, 2014.

O. Ganslandt, Proton magnetic resonance spectroscopic imaging integrated into image-guided surgery: Correlation to standard magnetic resonance imaging and tumor cell density, Neurosurgery, vol.56, pp.291-299, 2005.

A. A. Garcia, Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital phase II consortia, Journal of Clinical Oncology, vol.26, issue.1, pp.76-82, 2008.

S. M. Garg, Traceable PEO-poly(ester) micelles for breast cancer targeting: The effect of core structure and targeting peptide on micellar tumor accumulation, Biomaterials, vol.144, pp.17-29, 2017.

T. Garg, Current strategies for targeted delivery of bio-active drug molecules in the treatment of brain tumor, Journal of Drug Targeting, vol.23, issue.10, pp.865-87, 2015.

N. Garrido, Cisplatin-mediated impairment of mitochondrial DNA metabolism inversely correlates with glutathione levels, The Biochemical Journal, vol.414, issue.1, pp.93-102, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00478928

R. Garzon, G. A. Calin, and C. M. Croce, MicroRNAs in cancer, Annual Review of Medicine, vol.60, issue.1, pp.167-79, 2009.

G. Gaucher, Block copolymer micelles: Preparation, characterization and application in drug delivery, Journal of Controlled Release, vol.109, issue.1-3, pp.169-88, 2005.

C. F. Geraldes and S. Laurent, Classification and basic properties of contrast agents for magnetic resonance imaging, Contrast Media & Molecular Imaging, vol.4, issue.1, pp.1-23, 2009.

D. Gibson, Multi-action Pt(IV) anticancer agents; do we understand how they work, Journal of Inorganic Biochemistry, vol.191, pp.77-84, 2019.

S. Grand, , 2006.

H. and P. , diffusion : Quelle place pour ces techniques lors du diagnostic et du suivi des principales tumeurs cérébrales sus-tentorielles de l'adulte ?, Revue Neurologique, vol.162, issue.12, pp.1204-1224

R. Gref, Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): Influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption, Colloids and Surfaces B: Biointerfaces, vol.18, issue.3-4, pp.301-314, 2000.

M. Grogna, Polymer micelles decorated by gadolinium complexes as MRI blood contrast agents: Design, synthesis and properties, Polymer Chemistry, vol.1, issue.9, pp.1485-90, 2010.

M. Grogna, R. Cloots, A. Luxen, C. Jérôme, C. Passirani et al., Convenient grafting through approach for the preparation of stealth polymeric blood pool magnetic resonance imaging contrast agents, Journal of Polymer Science Part A: Polymer Chemistry, vol.49, issue.17, pp.3700-3708, 2011.

M. Grogna, R. Cloots, A. Luxen, C. Jérôme, C. Passirani et al., Stealth macromolecular platforms for the design of MRI blood pool contrast agents, Polymer Chemistry, vol.2, issue.10, p.2316, 2011.

J. Gross, Nanoparticle tracking analysis of particle size and concentration detection in suspensions of polymer and protein samples: Influence of experimental and data evaluation parameters, European Journal of Pharmaceutics and Biopharmaceutics, vol.104, pp.30-41, 2016.

P. Grossen, PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application, Journal of Controlled Release, vol.260, pp.46-60, 2017.

E. C. Gryparis, Effect of conditions of preparation on the size and encapsulation properties of PLGA-mPEG nanoparticles of cisplatin, Drug Delivery, vol.14, issue.6, pp.371-80, 2007.

A. D. Guminski, MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma, Gynecologic Oncology, vol.100, issue.2, pp.239-285, 2006.

S. Guo, Lipid-coated cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy, ACS Nano, vol.7, issue.11, pp.9896-904, 2013.

J. F. Hainfeld, Radiotherapy enhancement with gold nanoparticles, Journal of Pharmacy and Pharmacology, vol.60, issue.8, pp.977-85, 2008.

J. F. Hainfeld, Gold nanoparticles enhance the radiation therapy of a murine squamous cell carcinoma, Physics in Medicine and Biology, vol.55, issue.11, pp.3045-59, 2010.

J. F. Hainfeld, Gold nanoparticle imaging and radiotherapy of brain tumors in mice, Nanomedicine, vol.8, issue.10, pp.1601-1610, 2013.

J. F. Hainfeld, D. N. Slatkin, and H. M. Smilowitz, The use of gold nanoparticles to enhance radiotherapy in mice, Physics in Medicine and Biology, vol.49, issue.18, pp.309-324, 2004.

A. G. Hall and M. J. Tilby, Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies, Blood Reviews, vol.6, issue.3, pp.163-73, 1992.

M. D. Hall, The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy, Annual Review of Pharmacology and Toxicology, vol.48, issue.1, pp.495-535, 2008.

I. W. Hamley, Block copolymers in solution: Fundamentals and applications, 2005.

D. Hanahan and R. A. Weinberg, The hallmarks of cancer, Cell, vol.100, issue.1, pp.57-70, 2000.

D. Hanahan and R. A. Weinberg, Hallmarks of cancer: The next generation, Cell, vol.144, issue.5, pp.646-74, 2011.

F. Hanif, Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment, Asian Pacific Journal of Cancer Prevention, vol.18, issue.1, pp.3-9, 2017.

S. Hann, Novel separation method for highly sensitive speciation of cancerostatic platinum compounds by HPLC-ICP-MS, Analytical and Bioanalytical Chemistry, vol.381, issue.2, pp.405-417, 2005.

B. W. Harper, Advances in platinum chemotherapeutics, Chemistry -A European Journal, vol.16, issue.24, pp.7064-77, 2010.

M. E. Hegi, MGMT gene silencing and benefit from temozolomide in glioblastoma, The New England Journal of Medicine, vol.352, issue.10, pp.997-1003, 2005.

C. Hennequin and V. Favaudon, Biological basis for chemo-radiotherapy interactions, European Journal of Cancer, vol.38, issue.2, pp.223-253, 2002.

E. Herraez, Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins, Molecular Pharmaceutics, vol.9, issue.9, pp.2565-76, 2012.

H. Hillaireau and P. Couvreur, Nanocarriers' entry into the cell: Relevance to drug delivery, Cellular and Molecular Life Sciences, vol.66, issue.17, pp.2873-96, 2009.

F. J. Hoebers, Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: Lack of correlation between normal tissues and primary tumor, Cancer Chemotherapy and Pharmacology, issue.6, pp.1075-81, 2008.

M. R. Horsman, Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. A review, Acta Oncologica, vol.34, issue.5, pp.571-87, 1995.

W. Y. Hung, Somatic mutations in mitochondrial genome and their potential roles in the progression of human gastric cancer, Biochimica et Biophysica Acta, vol.1800, issue.3, pp.264-70, 2010.

J. Hurley, Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer, Journal of Clinical Oncology, vol.24, issue.12, pp.1831-1839, 2006.

V. T. Huynh, Block copolymer micelles with pendant bifunctional chelator for platinum drugs: Effect of spacer length on the viability of tumor cells, Biomacromolecules, vol.13, issue.4, pp.1010-1033, 2012.

K. Jaaback, N. Johnson, and L. Ta, Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer (Review), Cochrane Database of Systematic Reviews, p.5340, 2016.

J. Jenab-wolcott and B. J. Giantonio, Bevacizumab: Current indications and future development for management of solid tumors, Expert Opinion on Biological Therapy, vol.9, issue.4, pp.507-524, 2009.

C. Jérôme and P. Lecomte, Recent advances in the synthesis of aliphatic polyesters by ring-opening polymerization, Advanced Drug Delivery Reviews, vol.60, issue.9, pp.1056-76, 2008.

C. Jin, The effect of paclitaxel-loaded nanoparticles with radiation on hypoxic MCF-7 cells, Journal of Clinical Pharmacy and Therapeutics, vol.32, issue.1, pp.41-48, 2007.

T. C. Johnstone, K. Suntharalingam, and S. J. Lippard, Third row transition metals for the treatment of cancer, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences, vol.373, p.20140185, 2015.

T. C. Johnstone, K. Suntharalingam, and S. J. Lippard, The next generation of platinum drugs: Targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs, Chemical Reviews, vol.116, issue.5, pp.3436-86, 2016.

B. Kaina, G. P. Margison, and M. Christmann, Targeting O 6 -methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy, Cellular and Molecular Life Sciences, vol.67, issue.21, pp.3663-81, 2010.

L. S. Karfeld-sulzer, Multivalent protein polymer MRI contrast agents: Controlling relaxivity via modulation of amino acid sequence, Biomacromolecules, vol.11, issue.6, pp.1429-1465, 2010.

M. Kartalou and J. M. Essigmann, Mechanisms of resistance to cisplatin, Mutation Research, vol.478, issue.1-2, pp.23-43, 2001.

K. Kataoka, A. Harada, and Y. Nagasaki, Block copolymer micelles for drug delivery: Design, characterization and biological significance, Advanced Drug Delivery Reviews, vol.64, pp.37-48, 2012.

J. J. Kavanagh, Multi-institutional phase 2 study of TLK286 (TELCYTA?, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer, International Journal of Gynecological Cancer, vol.15, issue.4, pp.593-600, 2005.

L. Kelland, The resurgence of platinum-based cancer chemotherapy, Nature Reviews Cancer, vol.7, issue.8, pp.573-84, 2007.

I. A. Khalil, Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery, Pharmacological Reviews, vol.58, issue.1, pp.32-45, 2006.

W. J. Kil, In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide, Clinical Cancer Research, vol.14, issue.3, pp.931-939, 2008.

S. Kohsaka and S. Tanaka, Chemotherapeutic agent for glioma, Clinical Management and Evolving Novel Therapeutic Strategies for Patients with Brain Tumors. Terry Lichtor, pp.415-453, 2013.

N. L. Komarova, Cancer: A moving target, Nature, vol.525, pp.198-207, 2015.

M. Koshy, Improved survival time trends for glioblastoma using the SEER 17 population-based registries, Journal of Neurooncology, vol.107, issue.1, pp.207-219, 2012.

A. Kowalczuk, Star-shaped nano-conjugates of cisplatin with high drug payload, International Journal of Pharmaceutics, vol.404, issue.1-2, pp.220-250, 2011.

M. T. Krauze, Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging, Brain Research Protocols, vol.16, issue.1-3, pp.20-26, 2005.

M. T. Krauze, Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts, Neuro-Oncology, vol.9, issue.4, pp.393-403, 2007.

H. Kubota, Feasibility of metronomic chemotherapy with tegafur-uracil, cisplatin, and dexamethasone for docetaxel-refractory prostate cancer, Journal of Rural Medicine, vol.12, issue.2, pp.112-121, 2017.

H. Landy, Pilot study of estramustine added to radiosurgery and radiotherapy for treatment of high grade glioma, Journal of Neurooncology, vol.67, issue.1-2, pp.215-235, 2004.

V. Laquintana, New strategies to deliver anticancer drugs to brain tumors, Expert Opinion on Drug Delivery, vol.6, issue.10, pp.1017-1049, 2009.

S. Lauro, The use of bevacizumab in non-small cell lung cancer: An update, Anticancer Research, vol.34, issue.4, pp.1537-1582, 2014.

R. Lehner, Intelligent nanomaterials for medicine: Carrier platforms and targeting strategies in the context of clinical application, Nanomedicine: Nanotechnology, Biology, and Medicine, vol.9, issue.6, pp.742-57, 2013.

C. Lemarchand, Influence of polysaccharide coating on the interactions of nanoparticles with biological systems, Biomaterials, vol.27, issue.1, pp.108-126, 2006.

J. Lemée, Au-delà des frontières du glioblastome : Caractérisation de la zone péritumorale des glioblastomes. Médecine humaine et pathologie, 2015.

G. Lenglet, Mécanisme d'action de nouveaux agents alkylants ciblant l'ADN ou les protéines. Médecine humaine et pathologie, 2012.

E. Lepeltier, C. Bourgaux, and P. Couvreur, Nanoprecipitation and the "Ouzo effect": Application to drug delivery devices, Advanced Drug Delivery Reviews, vol.71, pp.86-97, 2014.

J. Li, Complex of cisplatin with biocompatible poly(ethylene glycol) with pendant carboxyl groups for the effective treatment of liver cancer, Journal of Applied Polymer Science, vol.131, issue.18, pp.9246-54, 2014.

Q. Li, Contribution of organic cation transporter 3 to cisplatin cytotoxicity in human cervical cancer cells, Journal of Pharmaceutical Sciences, vol.101, issue.1, pp.394-404, 2012.

S. Li, A common profile for polymer-based controlled releases and its logical interpretation to general release process, Journal of Pharmacy & Pharmaceutical Sciences, vol.9, issue.2, pp.238-282, 2006.

S. Li, Overcoming resistance to cisplatin by inhibition of glutathione S-transferases (GSTs) with ethacraplatin micelles in vitro and in vivo, Biomaterials, vol.144, pp.119-148, 2017.

T. Li, Magnetic resonance imaging of folic acid-coated magnetite nanoparticles reflects tissue biodistribution of long-acting antiretroviral therapy, International Journal of Nanomedicine, vol.10, pp.3779-90, 2015.

B. C. Liang and E. Ullyatt, Increased sensitivity to cis-diamminedichloroplatinum induced apoptosis with mitochondrial DNA depletion, Cell Death & Differentiation, vol.5, issue.8, pp.694-701, 1998.

F. Lieberman, Glioblastoma update: Molecular biology, diagnosis, treatment, response assessment, and translational clinical trials, vol.6, p.1892, 1000.

Y. Ling, Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma, International Journal of Pharmaceutics, vol.430, issue.1-2, pp.266-75, 2012.

G. Liu, Cytotoxicity study of polyethylene glycol derivatives, vol.7, pp.18252-18261, 2017.

M. Y. Lombardi and M. Assem, Glioblastoma genomics: A very complicated story, Glioblastoma. Codon Publications, pp.3-25, 2017.

F. Lordick, Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.27, pp.50-57, 2016.

D. N. Louis, The 2016 World Health Organization classification of tumors of the central nervous system: A summary, Acta Neuropathologica, vol.131, issue.6, pp.803-823, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01479018

J. Lu, L. K. Sharma, and Y. Bai, Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis, Cell Research, vol.19, issue.7, pp.802-817, 2009.

M. Luchette, Radiation dose enhancement of gadolinium-based AGuIX nanoparticles on HeLa cells, Nanomedicine: Nanotechnology, Biology, and Medicine, vol.10, issue.8, pp.1751-1756, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01115659

H. Maeda, Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity, Advanced Drug Delivery Reviews, vol.91, pp.3-6, 2015.

H. Maeda, H. Nakamura, and J. Fang, The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo, Advanced Drug Delivery Reviews, vol.65, issue.1, pp.71-80, 2013.

H. Maeda, K. Tsukigawa, and J. Fang, A retrospective 30 years after discovery of the enhanced permeability and retention effect of solid tumors: Next-generation chemotherapeutics and photodynamic therapy-problems, solutions, and prospects, vol.23, pp.173-82, 2016.

Y. Mai and A. Eisenberg, Self-assembly of block copolymers, Chemical Society Reviews, vol.41, issue.18, p.5969, 2012.

I. Manavitehrani, Biomedical applications of biodegradable polyesters, Polymers, vol.8, issue.1, p.20, 2016.

R. Mandal, M. B. Sawyer, and X. Li, Mass spectrometry study of hemoglobinoxaliplatin complexes in colorectal cancer patients and potential association with chemotherapeutic responses, Rapid Communications in Mass Spectrometry, vol.20, issue.17, pp.2533-2541, 2006.

A. Mandic, Cisplatin induces endoplasmic reticulum stress and nucleusindependent apoptotic signaling, The Journal of Biological Chemistry, vol.278, issue.11, pp.9100-9106, 2003.

S. Marrache, R. K. Pathak, and S. Dhar, Detouring of cisplatin to access mitochondrial genome for overcoming resistance, Proceedings of the National Academy of Sciences, vol.111, issue.29, pp.10444-10453, 2014.

I. Martel-lafay, Radiothérapie et traitements combinés des cancers bronchiques non à petites cellules localement avancés, Oncologie, vol.18, issue.6, pp.385-91, 2016.

C. Marth, Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.28, pp.72-83, 2017.

D. Matei, Epigenetic resensitization to platinum in ovarian cancer, Cancer Research, vol.72, issue.9, pp.2197-205, 2012.

M. Matsumoto, T. Tsuchida, and K. Kawamoto, Cisplatin-induced cell death in human glioma, International Journal of Oncology, vol.11, issue.6, pp.1209-1221, 1997.

S. Matsumura, Mechanism of biodegradation, Biodegradable Polymers for Industrial Applications, pp.357-410, 2005.

Y. Matsumura and K. Kataoka, Preclinical and clinical studies of anticancer agentincorporating polymer micelles, Cancer Science, vol.100, issue.4, pp.572-581, 2009.

Y. Matsumura and H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer research, vol.46, pp.6387-92, 1986.

Y. Matsumura, Polymeric micellar delivery systems in oncology, Japanese Journal of Clinical Oncology, vol.38, issue.12, pp.793-802, 2008.

G. Mattheolabakis, In vivo investigation of tolerance and antitumor activity of cisplatin-loaded PLGA-mPEG nanoparticles, European Journal of Pharmaceutics and Biopharmaceutics, vol.71, issue.2, pp.190-195, 2009.

J. R. Mccarthy and R. Weissleder, Multifunctional magnetic nanoparticles for targeted imaging and therapy, Advanced Drug Delivery Reviews, vol.60, issue.11, pp.1241-51, 2008.

M. A. Meier, PEO-b-PCL block copolymers: Synthesis, detailed characterization, and selected micellar drug encapsulation behavior, Macromolecular Rapid Communications, vol.26, issue.24, pp.1918-1942, 2005.

R. E. Meyn and D. Murray, Cell cycle effects of alkylating agents, Pharmacology & Therapeutics, vol.24, issue.2, pp.147-63, 1984.

R. Mezencev, Interactions of cisplatin with non-DNA targets and their influence on anticancer activity and drug toxicity: The complex world of the platinum complex, Current Cancer Drug Targets, vol.14, issue.9, pp.794-816, 2015.

P. Mi, Gd-DTPA-loaded polymer-metal complex micelles with high relaxivity for MR cancer imaging, Biomaterials, vol.34, issue.2, pp.492-500, 2013.

I. Miladi, Combining ultrasmall gadolinium-based nanoparticles with photon irradiation overcomes radioresistance of head and neck squamous cell carcinoma, Nanomedicine: Nanotechnology, Biology, and Medicine, vol.11, issue.1, pp.247-57, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01053787

S. E. Miller and D. A. House, The hydrolysis products of cisdichlorodiammineplatinum(II) 2. The kinetics of formation and anation of the cisdiamminedi(aqua)platinum(II) cation, Inorganica Chimica Acta, vol.166, pp.189-97, 1989.

T. Minko, P. Kopecková, and J. Kopecek, Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells, Pharmaceutical Research, vol.16, issue.7, pp.986-96, 1999.

T. Minko, P. Kopecková, and J. Kopecek, Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma, International Journal of Cancer, vol.86, issue.1, pp.108-125, 2000.

S. Mizutani, Mutations in the mitochondrial genome confer resistance of cancer cells to anticancer drugs, Cancer Science, vol.100, issue.9, pp.1680-1687, 2009.

I. Montes-burgos, Characterisation of nanoparticle size and state prior to nanotoxicological studies, Journal of Nanoparticle Research, vol.12, issue.1, pp.47-53, 2010.

D. Moreno, Pharmacodynamics of cisplatin-loaded PLGA nanoparticles administered to tumor-bearing mice, European Journal of Pharmaceutics and Biopharmaceutics, vol.74, issue.2, pp.265-74, 2010.

M. A. Moses, H. Brem, and R. Langer, Novel delivery systems in cancer chemotherapy, Science and Medicine, vol.9, issue.5, pp.264-73, 2003.

F. Mouffouk, Self-assembled polymeric nanoparticles as new, smart contrast agents for cancer early detection using magnetic resonance imaging, International Journal of Nanomedicine, vol.10, pp.63-76, 2015.

M. M. Mrugala, Advances and challenges in the treatment of glioblastoma: A clinician's perspective, Discovery Medicine, vol.15, issue.83, pp.221-251, 2013.

B. Mukherjee, EGFRvIII and DNA double-strand break repair: A molecular mechanism for radioresistance in glioblastoma, Cancer Research, vol.69, issue.10, pp.4252-4261, 2009.

M. Murakami, Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting, Science Translational Medicine, vol.3, issue.64, pp.64-66, 2011.

H. Na, . Bin, I. C. Song, and T. Hyeon, Inorganic nanoparticles for MRI contrast agents, Advanced Materials, vol.21, issue.21, pp.2133-2181, 2009.

Y. Nakamura, Nanodrug delivery: Is the enhanced permeability and retention effect sufficient for curing cancer?, Bioconjugate Chemistry, vol.27, issue.10, pp.2225-2263, 2016.

E. Nance, Non-invasive delivery of stealth, brain-penetrating nanoparticles across the blood-brain barrier using MRI-guided focused ultrasound, Journal of Controlled Release, vol.189, pp.123-155, 2014.

S. Nazir, Nanomaterials in combating cancer: Therapeutic applications and developments, Nanomedicine: Nanotechnology, Biology, and Medicine, vol.10, issue.1, pp.19-34, 2014.

U. Ndagi, N. Mhlongo, and M. E. Soliman, Metal complexes in cancer therapy -An update from drug design perspective. Drug Design, Development and Therapy, vol.11, pp.599-616, 2017.

N. Nishiyama and K. Kataoka, Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery, Pharmacology and Therapeutics, vol.112, issue.3, pp.630-678, 2006.

N. Nishiyama, Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice, Cancer Research, vol.63, issue.24, pp.8977-83, 2003.

D. M. Noll, T. M. Mason, and P. S. Miller, Formation and repair of interstrand cross-links in DNA, Chemical Reviews, vol.106, issue.2, pp.277-301, 2006.

S. Novello, Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.27, pp.1-27, 2016.

S. O'grady, The role of DNA repair pathways in cisplatin resistant lung cancer, Cancer Treatment Reviews, vol.40, issue.10, pp.1161-70, 2014.

J. A. Oberg, Neurocognitive functioning and quality of life in patients with recurrent malignant gliomas treated on a phase Ib trial evaluating topotecan by convectionenhanced delivery, Neuro-Oncology Practice, vol.1, issue.3, pp.94-100, 2014.

C. Oerlemans, Polymeric micelles in anticancer therapy: Targeting, imaging and triggered release, Pharmaceutical Research, vol.27, issue.12, pp.2569-89, 2010.

A. Olar and K. D. Aldape, Biomarkers classification and therapeutic decision-making for malignant gliomas, Current Treatment Options in Oncology, vol.13, issue.4, pp.417-453, 2012.

J. Oldenburg, Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.24, pp.125-132, 2013.

K. Osada, R. J. Christie, and K. Kataoka, Polymeric micelles from poly(ethylene glycol)-poly(amino acid) block copolymer for drug and gene delivery, Journal of The Royal Society Interface, issue.6, pp.325-339, 2009.

Q. Ostrom, Gene markers in brain tumors: What the epileptologist should know, Epilepsia, vol.54, pp.25-34, 2013.

C. P. Page, G. Cheymol, and J. Duteil, , 1999.

M. Parhizkar, Electrohydrodynamic encapsulation of cisplatin in poly (lactic-coglycolic acid) nanoparticles for controlled drug delivery, Nanomedicine: Nanotechnology, Biology, and Medicine, vol.12, issue.7, pp.1919-1948, 2016.

E. Pasquier, M. Kavallaris, and N. André, Metronomic chemotherapy: New rationale for new directions, Nature Reviews Clinical Oncology, vol.7, issue.8, pp.455-65, 2010.

V. M. Patil, A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck, Oral Oncology, vol.51, issue.3, pp.279-86, 2015.

H. K. Patra and A. P. Turner, The potential legacy of cancer nanotechnology: Cellular selection, Trends in Biotechnology, vol.32, issue.1, pp.21-31, 2014.

D. Peer, Nanocarriers as an emerging platform for cancer therapy, Nature Nanotechnology, vol.2, issue.12, pp.751-60, 2007.

M. D. Pegram, Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer, Journal of the National Cancer Institute, vol.96, issue.10, pp.759-69, 2004.

S. Penczek, Living ring-opening polymerizations of heterocyclic monomers, Progress in Polymer Science, vol.32, issue.2, pp.247-82, 2007.

N. A. Peppas and J. J. Sahlin, A simple equation for the description of solute release. III. Coupling of diffusion and relaxation, International Journal of Pharmaceutics, vol.57, issue.2, pp.169-72, 1989.

E. Porcel, Gadolinium-based nanoparticles to improve the hadrontherapy performances, Nanomedicine: Nanotechnology, Biology, and Medicine, vol.10, issue.8, pp.1601-1609, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01115636

P. E. Postmus, Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.28, pp.1-21, 2017.

P. Pourquier, Alkylating agents, Bulletin du Cancer, vol.98, issue.11, pp.1237-51, 2011.

L. A. Pray, Gleevec: The breakthrough in cancer treatment, Nature Education, vol.1, issue.1, p.37, 2008.

A. W. Prestayko, Cisplatin (cis-diamminedichloroplatinum II), Cancer Treatment Reviews, vol.6, issue.1, pp.17-39, 1979.

W. Qi, Aqueous self-assembly of poly(ethylene oxide)-blockpoly(?caprolactone) (PEO-b-PCL) copolymers: Disparate diblock copolymer compositions give rise to nano-and meso-scale bilayered vesicles, Nanoscale, vol.5, issue.22, pp.10908-10923, 2013.

Z. M. Qian, Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway, Pharmacological Reviews, vol.54, issue.4, pp.561-87, 2002.

J. A. Quinn, Phase II trial of temozolomide plus O 6 -benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma, Journal of Clinical Oncology, vol.27, issue.8, pp.1262-1269, 2009.

F. L. Reboul, Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: Preclinical and early clinical data, Hematology/Oncology Clinics of North America, vol.18, issue.1, pp.41-53, 2004.

W. Rima, Internalization pathways into cancer cells of gadolinium-based radiosensitizing nanoparticles, Biomaterials, vol.34, issue.1, pp.181-95, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00757773

C. R. Rocha, Glutathione depletion sensitizes cisplatin-and temozolomideresistant glioma cells in vitro and in vivo, Cell Death and Disease, vol.5, issue.10, p.1505, 2014.

W. P. Roos, Apoptosis in malignant glioma cells triggered by the temozolomideinduced DNA lesion O 6 -methylguanine, Oncogene, vol.26, issue.2, pp.186-97, 2007.

J. Rousseau, Enhanced survival and cure of F98 glioma-bearing rats following intracerebral delivery of carboplatin in combination with photon irradiation, Clinical Cancer Research, vol.13, issue.17, pp.5195-201, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00410458

J. Rousseau, Efficacy of intracerebral delivery of carboplatin in combination with photon irradiation for treatment of F98 glioma-bearing rats, International Journal of Radiation Oncology, vol.73, issue.2, pp.530-536, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00410447

J. Rousseau, Efficacy of intracerebral delivery of cisplatin in combination with photon irradiation for treatment of brain tumors, Journal of Neurooncology, vol.98, issue.3, pp.287-95, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00622594

R. Saito, Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging, Cancer Research, vol.64, issue.7, pp.2572-2581, 2004.

R. Saito, Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain, Experimental Neurology, vol.196, issue.2, pp.381-390, 2005.

L. Sancey, The use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy, The British Journal of Radiology, vol.87, p.20140134, 1041.
URL : https://hal.archives-ouvertes.fr/hal-01286747

D. P. Sanders, Synthesis of functionalized cyclic carbonate monomers using a versatile pentafluorophenyl carbonate intermediate, JACS Communications, vol.132, pp.14724-14730, 2010.

S. Sarkar, Tailor-made self-assemblies from functionalized amphiphiles: Diversity and applications, Langmuir, issue.36, pp.10449-68, 2018.

O. G. Scharovsky, L. E. Mainetti, and V. R. Rozados, Metronomic chemotherapy: Changing the paradigm that more is better, Current Oncology, vol.16, issue.2, pp.7-15, 2009.

D. Séhédic, Nanomedicine to overcome radioresistance in glioblastoma stem-like cells and surviving clones, Trends in Pharmacological Sciences, vol.36, issue.4, pp.236-52, 2015.

H. Seyednejad, Functional aliphatic polyesters for biomedical and pharmaceutical applications, Journal of Controlled Release, vol.152, issue.1, pp.168-76, 2011.

K. Seystahl, Therapeutic options in recurrent glioblastoma-An update, Critical Reviews in Oncology/Hematology, vol.99, pp.389-408, 2016.

B. Shen, Topotecan-loaded mesoporous silica nanoparticles for reversing multidrug resistance by synergetic chemoradiotherapy, Chemistry -An Asian Journal, vol.10, issue.2, pp.344-352, 2015.

D. Shen, Cisplatin resistance: A cellular self-defense mechanism resulting from multiple epigenetic and genetic changes, Pharmacological Reviews, vol.64, issue.3, pp.706-727, 2012.

W. Shen, Thermogelling polymer-platinum(IV) conjugates for long-term delivery of cisplatin, Biomacromolecules, vol.16, issue.1, pp.105-120, 2015.

W. Shen, Sustained codelivery of cisplatin and paclitaxel via an injectable prodrug hydrogel for ovarian cancer treatment, ACS Applied Materials & Interfaces, vol.9, issue.46, pp.40031-40077, 2017.

Y. Shen, T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7 T. Investigative Radiology, vol.50, pp.330-338, 2015.

Y. A. Shen, Bypassing the EPR effect with a nanomedicine harboring a sustainedrelease function allows better tumor control, International Journal of Nanomedicine, vol.10, pp.2485-502, 2015.

M. A. Shenoy and B. B. Singh, Chemical radiosensitizers in cancer therapy, Cancer Investigation, vol.10, issue.6, pp.533-51, 1992.

L. Shi, MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity, Brain Research, vol.1352, pp.255-64, 2010.

M. Shi, Convection-enhancement delivery of platinum-based drugs and Lipoplatin TM to optimize the concomitant effect with radiotherapy in F98 glioma rat model, Investigational New Drugs, vol.33, issue.3, pp.555-63, 2015.

Z. H. Siddik, Mechanisms of action of cancer chemotherapeutic agents: DNAinteractive alkylating agents and antitumour platinum-based drugs, The Cancer Handbook 1st, 2002.

Z. H. Siddik, Cisplatin: Mode of cytotoxic action and molecular basis of resistance, Oncogene, vol.22, issue.47, pp.7265-79, 2003.

T. Siegal, Change clinical practice for brain tumor, Neuro-Oncology, vol.15, issue.6, pp.656-69, 2013.

E. C. Smyth, Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.27, pp.38-49, 2016.

C. Sonnenschein and A. M. Soto, The aging of the 2000 and 2011 Hallmarks of Cancer reviews: A critique, Journal of Biosciences, vol.38, issue.3, pp.651-63, 2013.

J. A. Sprowl, Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy, Clinical Pharmacology and Therapeutics, vol.91, issue.6, pp.1022-1028, 2012.

G. P. Stathopoulos and T. Boulikas, Lipoplatin formulation review article, Journal of Drug Delivery, p.581363, 2012.

G. P. Stathopoulos, Cisplatin: Process and future, Journal of the Balkan Union of Oncology, vol.18, issue.3, pp.564-573, 2013.

D. J. Stewart, Mechanisms of resistance to cisplatin and carboplatin, Critical Reviews in Oncology/Hematology, vol.63, issue.1, pp.12-31, 2007.

N. Strazielle and J. F. Ghersi-egea, Physiology of blood-brain interfaces in relation to brain disposition of small compounds and macromolecules, Molecular Pharmaceutics, vol.10, issue.5, pp.1473-91, 2013.

R. Stupp, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, The New England Journal of Medicine, vol.352, issue.10, pp.987-96, 2005.

R. Stupp, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-Year analysis of the EORTC-NCIC trial, The Lancet Oncology, vol.10, issue.5, pp.459-66, 2009.

W. H. Su, Metronomic therapy for gynecologic cancers, Taiwanese Journal of Obstetrics and Gynecology, vol.51, issue.2, pp.167-78, 2012.

X. Sun, A pH-responsive yolk-like nanoplatform for tumor targeted dual-mode magnetic resonance imaging and chemotherapy, ACS Nano, vol.11, issue.7, pp.7049-59, 2017.

A. F. Tamimi and M. Juweid, Epidemiology and outcome of glioblastoma, Glioblastoma. Codon Publications, pp.143-53, 2017.

T. Tippayamontri, Cellular uptake and cytoplasm/DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116, Investigational New Drugs, vol.29, issue.6, pp.1321-1328, 2011.

T. Tippayamontri, Synergism in concomitant chemoradiotherapy of cisplatin and oxaliplatin and their liposomal formulation in the human colorectal cancer HCT116 model, Anticancer Research, vol.32, issue.10, pp.4395-404, 2012.

R. C. Todd and S. J. Lippard, Consequences of cisplatin binding on nucleosome structure and dynamics, Chemistry & Biology, vol.17, issue.12, pp.1334-1377, 2010.

K. Tomoda, Examination of gossypol-pluronic micelles as potential radiosensitizers, The American Association of Pharmaceutical Scientists Journal, vol.17, issue.6, pp.1369-75, 2015.

Y. Torisawa, T. Nishi, and J. Minamikawa, NaBH4 in N-methylpyrrolidone: A safe alternative for hydride displacement reaction, Bioorganic & Medicinal Chemistry Letters, vol.11, issue.20, pp.2787-2796, 2001.

E. G. Trams, M. V. Nadkarni, and P. K. Smith, On the mechanism of action of the alkylating agents. I. Interaction of alkylating agents with nucleic acids, Cancer Research, vol.21, issue.4, pp.560-566, 1961.

A. M. Tsimberidou, Ultimate fate of oncology drugs approved by the US Food and Drug Administration without a randomized trial, Journal of Clinical Oncology, vol.27, issue.36, pp.6243-50, 2009.

H. Uchino, Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats, British Journal of Cancer, vol.93, issue.6, pp.678-87, 2005.

K. Van-butsele and S. Cajot, pH-Responsive flower-type micelles formed by a biotinylated poly(2-vinylpyridine)-block-poly(ethylene oxide)-block-poly(caprolactone) triblock copolymer, Advanced Functional Materials, vol.19, issue.9, pp.1416-1441, 2009.
URL : https://hal.archives-ouvertes.fr/hal-01389161

K. Van-butsele and C. Fustin, Self-assembly and pH-responsiveness of ABC miktoarm star terpolymers, Langmuir, vol.25, issue.1, pp.107-118, 2009.

M. W. Van-gisbergen, How do changes in the mtDNA and mitochondrial dysfunction influence cancer and cancer therapy? Challenges, opportunities and models, Mutation Research, vol.764, pp.16-30, 2015.

H. F. Van-thuijl, Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment, Acta Neuropathologica, vol.129, issue.4, pp.597-607, 2015.

P. Vangeyte, S. Gautier, and R. Jérôme, About the methods of preparation of poly(ethylene oxide)-b-poly(?-caprolactone) nanoparticles in water -Analysis by dynamic light scattering, Colloids and Surfaces A: Physicochemical and Engineering Aspects, vol.242, issue.1-3, pp.203-214, 2004.

I. Vergote, Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer, European Journal of Cancer, vol.45, issue.13, pp.2324-2356, 2009.

K. Vigneswaran, S. Neill, and C. G. Hadjipanayis, Beyond the World Health Organization grading of infiltrating gliomas: Advances in the molecular genetics of glioma classification, Annals of Translational Medicine, vol.3, issue.7, p.95, 2015.

J. G. Villablanca, A phase I new approaches to neuroblastoma therapy study of buthionine sulfoximine and melphalan with autologous stem cells for recurrent/refractory high-risk neuroblastoma, Pediatric Blood & Cancer, vol.63, issue.8, pp.1349-56, 2016.

R. Visone and C. M. Croce, MiRNAs and Cancer, The American Journal of Pathology, vol.174, issue.4, pp.1131-1139, 2009.

M. A. Vogelbaum and M. K. Aghi, Convection-enhanced delivery for the treatment of glioblastoma, Neuro-Oncology, vol.17, issue.S2, pp.3-8, 2015.

M. A. Vogelbaum, Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: Phase 1 study of final safety results, Neurosurgery, issue.5, pp.1031-1039, 2007.

M. A. Vogelbaum, Convection-enhanced delivery for treating brain tumors and selected neurological disorders: Symposium review, Journal of Neurooncology, vol.83, issue.1, pp.97-109, 2007.

M. D. Walker, T. A. Strike, and G. E. Sheline, An analysis of dose-effect relationship in the radiotherapy of malignant gliomas, International Journal of Radiation Oncology Biology Physics, vol.5, issue.10, pp.1725-1756, 1979.

D. Wang and S. J. Lippard, Cellular processing of platinum anticancer drugs, Nature Reviews Drug Discovery, vol.4, issue.4, pp.307-327, 2005.

H. Wang, REV3L confers chemoresistance to cisplatin in human gliomas: The potential of its RNAi for synergistic therapy, Neuro-Oncology, vol.11, issue.6, pp.790-802, 2009.

K. E. Warren, A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: A Pediatric Brain Tumor Consortium study, Journal of Neurooncology, vol.106, issue.3, pp.643-652, 2012.

G. P. Warwick, The mechanism of action of alkylating agents, Cancer Research, vol.23, issue.8, pp.1315-1348, 1963.

M. Weller, EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma, The Lancet Oncology, vol.15, issue.9, pp.395-403, 2014.

E. White, A phase I trial of carboplatin administered by convection-enhanced delivery to patients with recurrent/progressive glioblastoma multiforme, Contemporary Clinical Trials, vol.33, issue.2, pp.320-351, 2012.

G. D. Wilson, S. M. Bentzen, and P. M. Harari, Biologic basis for combining drugs with radiation, Seminars in Radiation Oncology, vol.16, issue.1, pp.2-9, 2006.

T. Wilson, M. Karajannis, and D. Harter, Glioblastoma multiforme: State of the art and future therapeutics, Surgical Neurology International, vol.5, issue.64, p.132138, 2014.

D. S. Wishart, DrugBank 5.0: A major update to the DrugBank database for, Nucleic Acids Research, vol.46, issue.D1, pp.1074-1082, 2018.

S. P. Wisnovsky, Targeting mitochondrial DNA with a platinum-based anticancer agent, Chemistry & Biology, vol.20, issue.11, pp.1323-1331, 2013.

M. A. Woodruff and D. W. Hutmacher, The return of a forgotten polymerPolycaprolactone in the 21st century, Progress in Polymer Science, vol.35, issue.10, pp.1217-56, 2010.

B. Wu and C. A. Davey, Platinum drug adduct formation in the nucleosome core alters nucleosome mobility but not positioning, Chemistry and Biology, vol.15, issue.10, pp.1023-1031, 2008.

T. Wu, Autophagy facilitates lung adenocarcinoma resistance to cisplatin treatment by activation of AMPK/mTOR signaling pathway. Drug Design, Development and Therapy, vol.9, pp.6421-6452, 2015.

J. Xu, E. Feng, and J. Song, Renaissance of aliphatic polycarbonates: New techniques and biomedical applications, Journal of Applied Polymer Science, vol.131, issue.5, pp.39822-51, 2014.

S. Xu, Supramolecular cisplatin-vorinostat nanodrug for overcoming drug resistance in cancer synergistic therapy, Journal of Controlled Release, vol.266, pp.36-46, 2017.

W. Xu, P. Ling, and T. Zhang, Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs, Journal of Drug Delivery, p.340315, 2013.

X. Xue, Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing mitochondrial dysfunction, Molecular Pharmaceutics, vol.9, issue.3, pp.634-678, 2012.

X. Xue, Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking, ACS Nano, vol.7, issue.12, pp.10452-64, 2013.

M. Yamasaki, Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma, British Journal of Cancer, vol.104, issue.4, pp.707-720, 2011.

Y. Yamashita, Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts1, Neuro-Oncology, vol.9, issue.1, pp.20-28, 2007.

F. Yang, Doxorubicin, DNA torsion, and chromatin dynamics, Biochimica et Biophysica Acta, vol.1845, issue.1, pp.84-93, 2014.

Q. Yang, Polymer nanoparticle delivery of dichloroacetate and DACH-Pt to enhance antitumor efficacy and lower systemic toxicity, Biomater. Sci, vol.4, issue.4, pp.661-670, 2016.

T. Yang, Anti-tumor efficiency of lipid-coated cisplatin nanoparticles co-loaded with microRNA-375, Theranostics, vol.6, issue.1, pp.142-54, 2016.

W. Yang, Convection-enhanced delivery of carboplatin in combination with radiotherapy for the treatment of brain tumors, Journal of Neurooncology, vol.101, issue.3, pp.379-90, 2011.

W. Yang, Radiation therapy combined with intracerebral administration of carboplatin for the treatment of brain tumors, Radiation Oncology, vol.9, p.25, 2014.

W. Yang, Revision of the concept of anti-angiogenesis and its applications in tumor treatment, Chronic Diseases and Translational Medicine, vol.3, issue.1, pp.33-40, 2017.

Y. Yang, MiR-136 promotes apoptosis of glioma cells by targeting AEG-1 and Bcl-2, FEBS Letters, vol.586, issue.20, pp.3608-3620, 2012.

Z. Yang, Cisplatin preferentially binds mitochondrial DNA and voltagedependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: Possible role in apoptosis, Clinical Cancer Research, vol.12, issue.19, pp.5817-5842, 2006.

H. Ye, Poly(?,l-glutamic acid)-cisplatin conjugate effectively inhibits human breast tumor xenografted in nude mice, Biomaterials, vol.27, issue.35, pp.5958-65, 2006.

H. Ye, Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models, Journal of Controlled Release, vol.220, pp.358-67, 2015.

W. Ye, The complexity of translating anti-angiogenesis therapy from basic science to the clinic, Developmental Cell, vol.37, issue.2, pp.114-139, 2016.

B. Yoo, Combination treatment with theranostic nanoparticles for glioblastoma sensitization to TMZ, Molecular Imaging and Biology, vol.16, issue.5, pp.680-689, 2014.

Y. Yuan, Targeted theranostic platinum(IV) prodrug with a built-in aggregationinduced emission light-up apoptosis sensor for noninvasive early evaluation of its therapeutic responses in situ, Journal of the American Chemical Society, vol.136, issue.6, pp.2546-54, 2014.

K. Zabielska-koczyw?s and R. Lechowski, The use of liposomes and nanoparticles as drug delivery systems to improve cancer treatment in dogs and cats, Molecules, vol.22, issue.12, p.2167, 2017.

C. Zhang, Convection enhanced delivery of cisplatin-loaded brain penetrating nanoparticles cures malignant glioma in rats, Journal of Controlled Release, vol.263, pp.112-121, 2017.

J. Zhang, M. F. Stevens, and T. D. Bradshaw, Temozolomide: Mechanisms of action, repair and resistance, Current Molecular Pharmacology, vol.5, issue.1, pp.102-116, 2012.

N. Zhang, Probing the interaction of cisplatin with cytochrome c by electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry, Analytical Chemistry, vol.84, issue.14, pp.6206-6218, 2012.

R. Zhang, Convection-enhanced delivery of SN-38-loaded polymeric micelles (NK012) enables consistent distribution of SN-38 and is effective against rodent intracranial brain tumor models, Drug Delivery, vol.23, issue.8, pp.2780-2786, 2015.

Y. Zhang and M. R. Maurizi, Mitochondrial ClpP activity is required for cisplatin resistance in human cells, Biochimica et Biophysica Acta -Molecular Basis of Disease, vol.1862, issue.2, pp.252-64, 2016.

N. Zhidkov, Continuous intraperitoneal carboplatin delivery for the treatment of late-stage ovarian cancer, Molecular Pharmaceutics, vol.10, pp.3315-3337, 2013.

J. Zhou, Novel delivery strategies for glioblastoma, Cancer, vol.18, issue.1, pp.89-99, 2012.

J. Zhou, FOXM1 modulates cisplatin sensitivity by regulating EXO1 in ovarian cancer, PLoS ONE, vol.9, issue.5, p.96989, 2014.

Z. Zhou, R. Singh, and M. M. Souweidane, Convection-enhanced delivery for diffuse intrinsic pontine glioma treatment, Current Neuropharmacology, vol.15, issue.1, pp.116-144, 2017.

H. Zhu, Responsive fluorescent Bi2O3@PVA hybrid nanogels for temperaturesensing, dual-modal imaging, and drug delivery, Biomaterials, vol.33, issue.10, pp.3058-69, 2012.

J. E. Ziello, Y. Huang, and I. S. Jovin, Cellular endocytosis and gene delivery, Molecular Medicine, vol.16, pp.222-231, 2010.

F. Zustovich, A phase II study of cisplatin and temozolomide in heavily pretreated patients with temozolomide-refractory high-grade malignant glioma, Anticancer Research, vol.29, issue.10, pp.4275-4284, 2009.